CERS Cerus (CERS) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001020214
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
109
13F, latest reported quarter
What the filings say about CERS
Insiders, 180 days
-$890.7K net sold
5 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$89.5K
1 notice
Cerus insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, CERUS CORP insiders sold a net $890.7K of stock across 131 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 30, 2026.
- The trade is 3.2% of the 936,657 shares held after it.
- No other insider sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Jensen Chrystal sold about $89.5K of CERS on Aug 17, 2026; 109 funds added in the latest 13F quarter.Context
- 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Jun 30, 2026.
- The trade is 0.7% of the 2,232,211 shares held after it.
- 3 other insiders sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Jayaraman Vivek K sold about $52.7K of CERS on Jul 16, 2026; 3 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Mar 12, 2026.
- The trade is 2.0% of the 5,053,036 shares held after it.
- 4 other insiders sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Greenman William Mariner sold about $299.9K of CERS on Jun 30, 2026; 4 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Mar 12, 2026.
- The trade is 3.2% of the 1,062,188 shares held after it.
- 4 other insiders sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Green Kevin Dennis sold about $99.1K of CERS on Jun 30, 2026; 4 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Mar 6, 2026.
- The trade is 2.5% of the 966,657 shares held after it.
- 4 other insiders sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Jensen Chrystal sold about $71.6K of CERS on Jun 30, 2026; 4 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.131 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$890.7K over 180 days
-$89.5K over 90 days
below 60% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
109 funds bought in last quarter
more than 65% of Medical Devices
Revenue
+16.1% year over year
more than 65% of Medical Devices
Margin
-6.7% net margin
more than 61% of Medical Devices
Buybacks
no share repurchases reported
Short interest
8.5% of the float short (float per yahoo 2026-10-27) · 9.4 days to cover · settled 2026-10-15
more than 81% of Medical Devices
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CERS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+57.0%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CERS: institutional holders (13F)
13F holdings, latest reported quarter
22,215,127 sh
$64.9M
17,932,099 sh
$52.4M
8,563,424 sh
$25.0M
6,395,431 sh
$18.7M
5,485,983 sh
$16.0M
Congress trades in CERS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CERS planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
CHRYSTAL NIKOLE JENSEN
Filed 2026-08-17
$89.5K
VIVEK K JAYARAMAN
Filed 2026-07-16
$52.7K
CERS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Jacob Discovery Fund
$495.5K position · as of 2026-05-31
3.1%
Wasatch Ultra Growth Fund
$9.3M position · as of 2026-06-30
2.0%
ARK Genomic Revolution ETF
$15.5M position · as of 2026-07-31
1.0%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$951.6K position · as of 2026-06-30
0.6%
Voya MI Dynamic Small Cap Fund
$963.5K position · as of 2026-05-31
0.5%
Invesco NASDAQ Future Gen 200 ETF
$91.2K position · as of 2026-05-31
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 2
2 active
2
Phase 3
0 active
1
Not applicable
1 active
What changed recently
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated He
2026-10-15 · Not Yet Recruiting → Enrolling By Invitation
,
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transf
2026-10-07 · Active Not Recruiting → Completed
Phase 3
Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects W
2026-09-23 · Completion moved 2027-10-01 → 2030-09-30
Phase 2
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCE
2026-09-22 · Completion moved 2026-07-30 → 2026-12-15
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
CERUS - DEVELOPMENT AND IMPLEMENTATION OF PATHOGEN REDUCTION TECHNOLOGY (PRT). IGF::OT::IGF · 2016-06-17
$185.2M
Department Of Health And Human Services
LICENSE PATHOGEN REDUCTION TECHNOLOGY (PRT) FOR RED BLOOD CELL (RBC) COMPONENTS TO REDUCE THE RISK O · 2024-09-30
$65.4M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.8M
$5.8M
$1.8M
-70%
-32%
2024
$3.0M
$2.1M
$1.2M
-78%
-24%
2023
$3.7M
$760.3K
$1.5M
-69%
-17%
2022
$5.3M
$120.3K
$2.0M
-47%
-21%
2021
$5.2M
$5.1M
$2.0M
-2%
+20%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $890.7K sold by insiders over 180 days, 109 funds added last quarter, $89.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CERS financials
Revenue growth
+16.1%
XBRL, annual
Net margin
-6.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM CERS
| FY Dec 2025 | n/a |
| FY Dec 2024 | $76.1M |
| FY Dec 2023 | $76.1M |
| FY Dec 2022 | $76.1M |
| FY Dec 2021 | $76.1M |
| Jun 2026 | $57.4M |
| Mar 2026 | $53.7M |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | $52.4M |
| Mar 2025 | $43.2M |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM CERS
| FY Dec 2025 | n/a |
| FY Dec 2024 | -27.5% |
| FY Dec 2023 | -49.3% |
| FY Dec 2022 | -56.3% |
| FY Dec 2021 | -71.5% |
| Jun 2026 | -5.1% |
| Mar 2026 | -3.1% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -10.9% |
| Mar 2025 | -17.8% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$1.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CERS
| FY Dec 2025 | $1.1M |
| FY Dec 2024 | $8.5M |
| FY Dec 2023 | -$47.8M |
| FY Dec 2022 | -$27.6M |
| FY Dec 2021 | -$34.8M |
| Jun 2026 | -$3.5M |
| Mar 2026 | -$3.3M |
| Dec 2025 | $4.9M |
| Sep 2025 | $94.0K |
| Jun 2025 | -$2.9M |
| Mar 2025 | -$956.0K |
| Dec 2024 | $4.0M |
| Sep 2024 | $3.3M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CERS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CERS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-10.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CERS
| FY Dec 2025 | -26.0% |
| FY Dec 2024 | -38.5% |
| FY Dec 2023 | -62.3% |
| FY Dec 2022 | -56.2% |
| FY Dec 2021 | -57.7% |
| Jun 2026 | -10.8% |
| Mar 2026 | -15.5% |
| Dec 2025 | -26.0% |
| Sep 2025 | -27.8% |
| Jun 2025 | -36.0% |
| Mar 2025 | -36.1% |
| Dec 2024 | -38.5% |
| Sep 2024 | -38.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-3.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CERS
| FY Dec 2025 | -7.4% |
| FY Dec 2024 | -10.5% |
| FY Dec 2023 | -18.0% |
| FY Dec 2022 | -18.8% |
| FY Dec 2021 | -23.7% |
| Jun 2026 | -3.2% |
| Mar 2026 | -4.4% |
| Dec 2025 | -7.4% |
| Sep 2025 | -7.9% |
| Jun 2025 | -9.5% |
| Mar 2025 | -9.6% |
| Dec 2024 | -10.5% |
| Sep 2024 | -10.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CERS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CERS
| FY Dec 2025 | -6.7% |
| FY Dec 2024 | -10.6% |
| FY Dec 2023 | -26.0% |
| FY Dec 2022 | -26.2% |
| FY Dec 2021 | -30.5% |
| Jun 2026 | -1.3% |
| Mar 2026 | -2.5% |
| Dec 2025 | -6.7% |
| Sep 2025 | -7.2% |
| Jun 2025 | -9.0% |
| Mar 2025 | -9.0% |
| Dec 2024 | -10.6% |
| Sep 2024 | -9.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CERS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CERS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-0.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield CERS
| FY Dec 2025 | +0.3% |
| FY Dec 2024 | +3.0% |
| FY Dec 2023 | -12.2% |
| FY Dec 2022 | -4.3% |
| FY Dec 2021 | -3.0% |
| Jun 2026 | -0.3% |
| Mar 2026 | -0.3% |
| Dec 2025 | +0.3% |
| Sep 2025 | +0.1% |
| Jun 2025 | +1.3% |
| Mar 2025 | +2.6% |
| Dec 2024 | +3.0% |
| Sep 2024 | -3.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CERS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $233.8M | $201.3M | $186.8M | $188.3M |
| Operating income | -$8.7M | -$14.2M | -$30.1M | -$34.1M |
| Net income | -$15.6M | -$20.9M | -$37.5M | -$42.8M |
| EPS (diluted) | -0.08 | -0.11 | -0.21 | -0.24 |
| Operating cash flow | $4.8M | $11.4M | -$43.2M | -$25.6M |
| Cash | $20.0M | $20.3M | $11.6M | $35.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
CERS Stock Sonar score 5/7 axes
Find similar shapesCompareCERS ranks highest on growth (65th percentile) and profitability (62nd), and lowest on insider conviction (18th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CERS filings, in plain words
Are Cerus insiders buying or selling CERS?
In the 180 days to 2026-10-28, Cerus insiders were net sellers, a net $890.7K across purchases and sales reported on Form 4, by 5 sellers.
Are there planned insider sales of CERS?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $89.5K of stock; the latest, by CHRYSTAL NIKOLE JENSEN, was filed 2026-08-17.
Read the full summary
In the 180 days to 2026-10-28, Cerus insiders were net sellers of CERS, a net $890.7K across purchases and sales reported on Form 4 by 5 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $89.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
